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 Fibroids are tumours of smooth muscle; usually they arise in the uterus where they may 
be very numerous. They are found in all races and any age after puberty. 
       This is a descriptive prospective hospital based   study, carried out in three hospitals 
in Khartoum state in the period from the 15th of september2004 to the 15th of March 2005 
to find factors which affect the type of operation done for myoma treatment and to know 
its complications and outcome.   
       A total of one hundred and fourteen women were included in the study. 
       Information about personal data, parity, and present history of the patient, size, site 
and number of the fibroids in addition to the intraoperative and postoperative periods was 
collected using a questionnaire.  
       The type & timing of intervention in the treatment of fibroids should be 
individualized to each patient according to many factors including age and future fertility 
plans.  
      It was found that myomectomy was the commonest used modality of treatment used 
in 67.5% of population. The majority of women (75.5%) were between 30 to 45 years old 
and the majority of them were nulliparous.  
       Nearly half of the women (50.9%) were asymptomatic, while menstrual disorders 
occurred in 25.4% of the study population and pressure symptoms in 23.7%. 
       Women with fibroids of more than 16 weeks size were treated mostly with 
abdominal hysterectomy.  Most of the women (61.4%) had more than one fibroid. The 
recurrence rate of fibroids was close to that in the literature. 
       Abdominal hysterectomy was associated with more intraoperative blood loss and 
more blood transfusion, while myomectomy was associated with more postoperative 
complications.    
It was recommended that women should be counseled that hysterectomy is 





 ﻣﻠﺨﺺ  اﻷﻃﺮوﺣﺔ
ﻭﻴﻤﻜﻥ ﺃﻥ ﺘﻜﻭﻥ ﻤﻔﺭﺩﺓ ﺃﻭ , ﻤﻴﺔ ﺍﻟﺭﺤﻡ ﻫﻲ ﻭﺭﻡ ﻓﻲ ﺍﻟﻌﻀﻠﺔ ﺍﻟﻤﻠﺴﺎﺀ  ﺘﻨﻤﻭ ﻓﻲ ﺍﻟﺭﺤﻡ ﻟﺤ   
  . ﺘﻭﺠﺩ ﻓﻲ ﻜل ﺍﻷﺠﻨﺎﺱ ﻭﻜل ﺍﻷﻋﻤﺎﺭ ﺒﻌﺩ ﺍﻟﺒﻠﻭﻍ , ﻤﺘﻌﺩﺩﺓ 
ﺩﺭﺍﺴﺔ ﻭﺼﻔﻴﺔ ﻤﺴﺘﻘﺒﻠﻴﺔ  ﺃﺠﺭﻴﺕ ﻓﻲ ﺜﻼﺜﺔ ﻤﺴﺘﺸﻔﻴﺎﺕ ﻓﻲ ﻤﺤﺎﻓﻅﺔ ﺍﻟﺨﺭﻁﻭﻡ  ﻫﺫﻩ         
 ﻤﻥ ﺴﺒﺘﻤﺒﺭ ﺴﻨﺔ ﺃﺭﺒﻌﺔ ﻭﺃﻟﻔﻴﻥ ﺇﻟﻰ ﻓﻲ ﺍﻟﻤﺩﺓ ﻤﻥ ﺍﻟﺨﺎﻤﺱ ﻋﺸﺭ, ﻋﻠﻰ ﻤﺎﺌﺔ ﻭﺃﺭﺒﻌﺔ ﻋﺸﺭ ﺍﻤﺭﺃﺓ 
ﺍﻟﺨﺎﻤﺱ ﻋﺸﺭ ﻤﻥ ﻤﺎﺭﺱ ﺴﻨﺔ ﺨﻤﺴﺔ ﻭﺃﻟﻔﻴﻥ ﻹﻴﺠﺎﺩ ﺍﻟﻌﻭﺍﻤل ﺍﻟﺘﻲ ﺘﺅﺜﺭ ﻋﻠﻰ ﻨﻭﻉ ﺍﻟﻌﻤﻠﻴﺔ ﺍﻟﻤﺠﺭﺍﺓ 
  .ﻟﻤﻌﺎﻟﺠﺔ ﺍﻟﻠﺤﻤﻴﺔ ﻭﻤﻌﺭﻓﺔ ﺍﻟﻤﻀﺎﻋﻔﺎﺕ ﻭﺍﻟﻨﺘﺎﺌﺞ 
ﺤﺠﻡ ﻭﻤﻜﺎﻥ  , ﺔﺍﻟﺘﺎﺭﻴﺦ ﺍﻟﺸﺨﺼﻲ ﻟﻠﻤﺭﻴﻀ, ﻋﺩﺩ ﺍﻟﻭﻻﺩﺍﺕ , ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﻋﻥ ﺍﻟﺴﻴﺭﺓ ﺍﻟﺫﺍﺘﻴﺔ          
ﻠﺤﻤﻴﺎﺕ  ﺒﺎﻹﻀﺎﻓﺔ ﺇﻟﻰ ﻤﺩﺓ ﻤﻜﻭﺙ ﺍﻟﻤﺭﻴﻀﺔ ﺒﻌﺩ ﺍﻟﻌﻤﻠﻴﺔ ﺒﺎﻟﻤﺴﺘﺸﻔﻰ ﺠﻤﻌﺕ ﺒﻭﺍﺴﻁﺔ ﻭﻋﺩﺩ ﺍﻟ
  .ﺍﻻﺴﺘﺒﻴﺎﻥ 
 ﺒﺎﻟﺭﺠﻭﻉ ﺔﺘﻌﻴﻴﻥ ﻨﻭﻉ ﻭﻭﻗﺕ ﺍﻟﺘﺩﺨل ﻟﻌﻼﺝ ﺍﻟﻠﺤﻤﻴﺎﺕ ﻴﺠﺏ ﺃﻥ ﻴﺨﺼﺹ ﻟﻜل ﻤﺭﻴﻀ         
  .ﻟﻌﻭﺍﻤل ﻋﺩﺓ ﻤﺘﻀﻤﻨﺔ ﻟﻠﻌﻤﺭ ﻭﺍﻟﺨﻁﻁ ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ ﻟﻠﺨﺼﻭﺒﺔ 
. ﻴﻀﺎﺕ  ﻤﻥ ﺍﻟﻤﺭ% (5.76)ﻌﻼﺝ ﺍﻟﺠﺎﺭﻱ ﻓﻲ  ﺍﻟﻠﺤﻤﻴﺔ ﻜﺎﻥ ﻨﻭﻉ ﺍﻟلﻭﺠﺩ ﺃﻥ ﺍﺴﺘﺌﺼﺎ         
  .ﺴﻨﺔ ﻭﺃﻏﻠﺒﻴﺘﻬﻥ ﻟﻴﺱ ﻟﺩﻴﻬﻥ ﺃﻁﻔﺎل  (04-03) ﺒﻴﻥ  ﻥﻜﺎﻨﺕ ﺃﻋﻤﺎﺭﻫ%( 5.57)ﻠﺒﻴﺔ ﺍﻟﻨﺴﺎﺀ ﺃﻏ
ﺒﺎﻟﺭﻏﻡ ﻤﻥ ﺃﻥ ﺍﻀﻁﺭﺍﺒﺎﺕ ﺍﻟﺩﻭﺭﺓ , ﻟﻴﺱ ﻟﺩﻴﻬﻥ ّ ﺃﻋﺭﺍﺽ %( 9.05) ﺘﻘﺭﻴﺒﺎﹶ ﻨﺼﻑ ﺍﻟﻨﺴﺎﺀ          
 ﺍﻻﻨﺴﺠﺔ ﻁ ﺍﻟﻠﺤﻤﻴﺔ ﻋﻠﻰﻭﺃﻋﺭﺍﺽ ﻀﻐ, ﻤﻥ ﻤﺠﺘﻤﻊ ﺍﻟﺩﺭﺍﺴﺔ %( 4.52)ﺍﻟﺸﻬﺭﻴﺔ ﺘﺤﺩﺙ ﻓﻲ 
  %(.7.32) ﻓﻲ ﺍﻟﻤﺠﺎﻭﺭﺓ
ﺍﻟﺭﺤﻡ ﻋﺎﺩﺓ ﺘﻌﺎﻟﺞ ﺒﺎﺴﺘﺌﺼﺎل   ﺃﺴﺒﻭﻉ ﺤﺠﻡ61ﺍﻟﻨﺴﺎﺀ ﺍﻟﻼﺘﻲ ﻴﻌﺎﻨﻴﻥ ﻤﻥ ﺍﻟﻠﺤﻤﻴﺔ ﺃﻜﺜﺭ ﻤﻥ          
ﻤﻌﺩل ﺭﺠﻭﻉ . ﻜﺎﻥ ﻟﺩﻴﻬﻥ ﺃﻜﺜﺭ ﻤﻥ ﻟﺤﻤﻴﺔ ﻭﺍﺤﺩﺓ  %( 4.16)ﺃﻏﻠﺒﻴﺔ ﺍﻟﻨﺴﺎﺀ . ﺍﻟﺭﺤﻡ ﻋﺒﺭ ﺍﻟﺒﻁﻥ 
  . ﺕ ﺍﻟﺴﺎﺒﻘﺔ ﺍﻟﻠﺤﻤﻴﺔ  ﺘﻘﺭﻴﺒﺎﹰ ﻴﻌﺎﺩل ﺍﻟﻤﻭﺠﻭﺩ ﻓﻲ ﺍﻟﺩﺭﺍﺴﺎ
ﻭﺍﺴﺘﺌﺼﺎل , ﺍﺴﺘﺌﺼﺎل ﺍﻟﺭﺤﻡ ﻋﺒﺭ ﺍﻟﺒﻁﻥ ﻜﺎﻥ ﻤﺼﺤﻭﺒﺎﹶ ﺒﻨﺯﻴﻑ ﺩﺍﺨل ﺍﻟﻌﻤﻠﻴﺔ ﻭﻨﻘل ﺩﻡ           
  .ﺒﺎًﹶ ﺒﻤﻀﺎﻋﻔﺎﺕ ﺃﻜﺜﺭ ﺒﻌﺩ ﺍﻟﻌﻤﻠﻴﺔﺍﻟﻠﺤﻤﻴﺔ ﻜﺎﻥ ﻤﺼﺤﻭ
ﻭ ,ﻴﺠﺏ ﺃﻥ ﺘﺤﻀﺭ ﻜﻤﻴﺔ ﻭﺍﻓﺭﺓ ﻤﻥ ﺍﻟﺩﻡ ﻻﺴﺘﺌﺼﺎل ﺍﻟﺭﺤﻡ ﻭﺍﺴﺘﺌﺼﺎل ﺍﻟﻠﺤﻤﻴﺔ          
  . ﻤﻠﻴﺔ  ﻓﻲ ﻤﺴﺘﺸﻔﻴﺎﺘﻨﺎ ﻴﺠﺏ ﺃﻥ ﺘﻘﻠل ﻤﺩﺓ ﺒﻘﺎﺀ ﺍﻟﻤﺭﻴﺽ ﺒﻌﺩ ﺍﻟﻌ
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INTRODUCTION AND LITERATURE REVIEW 
 
 Fibroids are the commonest solid tumours of female genital tract and are found in all 
races and any age after puberty (1) ,they are found in 20%_25% of women aged over 
35years and rarely grow after the menopause(2). 
         Risk factors for clinically significant fibroids are nulliparity, obesity, a positive 
family history and African racial origin. (3) 
         A  Fibroid is a tumour of smooth muscle with a supporting structure of fibrous 
tissue. Some hyaline degeneration is present in all but smallest tumours and may be very 
extensive. Cystic degeneration in the centre of large fibroids is not uncommon; it is 
apparently due to avascular necrosis. Acute massive necrosis of fibroids occurs 
occasionally as a result of torsion or trauma. If the pedicle of a pedunculated subserous 
fibroid twists gradually, the omentum or sometimes the gut may adhere to the sticky 
fibrinous surface of the fibroid and eventually provide it with a blood supply which will 
keep it alive after its pedicle has sloughed. Red degeneration is almost always associated 
with pregnancy; its cause is unknown. Rarer, but of greater clinical significance is the 
marked cystic change occurring in large, usually subserous, fibroids during the later 
weeks of pregnancy(1).Leiomyosarcoma develops from a myoma with a recorded 
incidence of 0.1_0.5 %.(4)    
         Fibroids may be of any size from microscopic to massive (1), weighing more than 
45kg (100Ib) (4).usually they arise in the uterus where they may be very numerous and are 
described according to their position as subserous, intramural or submucous. In Africa, 
the United States and the West Indies fibroids seem to be commoner to develop earlier 
and to grow larger in Negro women than in Europeans. This is probably a true racial 
difference. Fibroids are frequently associated with primary or secondary -infertility. (1) 
         Pelvic inflammatory disease is frequently found in association with fibroids. (1) 
         The term fibroid has the sanction of long usage and will probably continue to be 
applied to this benign smooth muscle tumour of the uterus, although the alternative terms 
myoma, fibromyoma and leiomyoma are more precise. (1) 
Classification: 
         Uterine myomas originate in the myometrium and are classified by anatomic 
location. (4)  
         Submucous myomas lie just beneath the endometrium and tend to compress it as 
they grow toward the uterine lumen. They may develop pedicles and protrude fully into 
the cavity or even pass through the cervical canal while still attached within the corpus by 
along stalk .Here they are subject to torsion or infection.(4)  
         Intramural or interstitial myomas lie within the uterine wall, giving it a variable 
consistency. (4)  
         Subserous or subperitoneal tumors may lie just at the serosal surface of the uterus or 
may bulge outward from the myometrium. These external tumors tend to become 
pedunculated. If such a tumor acquires an extrauterine blood supply from omental 
vessels, its pedicle may atrophy and resorb; the tumors is then said to be parasitic. (4)  
Aetiology:       
         The aetiology of fibroids is unknown; indeed, it is not certain whether they should 
be regarded as true tumors or as a form of hyperplasia of the myometrium. (4) The cause 
of leiomyomas of the uterus is not known.Oestrogen stimulation of susceptible 
fibromuscular elements has been suggested.Myomas are known to increase in size with 
high dose oestrogen therapy and during pregnancy.Moreover,they decrease in size and 
even disappear following menpopause.Nevertheless,there is no solid evidence to suggest 
that oestrgens that oestrogens cause leimoyomas. 
 The hypothesis that human growth hormone (hGH) is related to  
the development of myomas has been largely dispelled by  
radioimmunoassay studies of hGH in pregnant patients and in patients  
taking estrogens. (4) 
Epidemiology and risk factors: 
         Leiomyomas have not been described in prepubrtal girls, but they are occasionally 
noted in their thirties or four ties, being detectable clinically in about 20% of women over 
30 years of age, and in approximately 80% of surgically removed uteri. Autopsy studies 
with systematic histology of the uterus show a prevalence of up to 50%. (3)  
         Relief of symptoms related to fibroids usually occurs at the time of menopause, 
when menstrual cyclicity and steroid hormone levels wane. However   , the increasing 
prevalence of hormone replacement therapy in the post reproductive years has led to 
more reports of women who become symptomatic or continued to have symptoms after 
the menopause. (5, 6) 
         Other reproductive factors that affect the risk of developing a leiomyoma   include: 
- Parity (having one or more pregnancies extending beyond 20 weeks) decreases the 
chance of fibroid formation. (7_9). 
 - Oral contraceptive pills (OCPs) can protect against clinically evident fibroids. In 
data provided by the Nurses Health Study, OCPs use increased risk of leiomyomas 
with early exposure to OCPs between the ages of 13 & 16. (9). 
- Smoking decreases the risk of having fibroids through an unknown mechanism. 
Smoking does not appear to affect estrogen metabolism.(7,10) 
- Significant consumption of beef, ham, or other red meats is associated with 
increased relative risk of fibroids and consumption of green vegetables with a 
decreased risk (11).  
- The relative risk of fibroids is tow to three fold greater in black than in white 
women.(12) Among women undergoing hysterectomy, black women are significantly 
more likely to have leiomyomas, to be younger at the time of diagnosis of fibroids 
and at hysterectomy, and to have more severe disease (e.g. higher uterine weights, 
greater likelihood of anaemia).(13) 
- Myomas are also common in obese women.(14) 
- Other risk factor is positive family history. (3) 
         Although there are high levels of both estrogen and progesterone during pregnancy 
and with OCPs use, both decrease the risk of fibroids. Thus influences other than steroid 
hormones are important to fibroid growth. It is possible that myoma formation is a 
response to injury, much like an atherosclerotic plaque that forms in response to hypoxia 
of arterial muscle Hypoxia of myometrial cells during menstruation may promote trans_ 
formation of normal myocytes to abnormal myocytes and subsequent leiomyomas. (15) 
Pathology : 
         A fibroid is a benign tumor of uterine smooth muscles termed a leiomyoma (3). 
         It is rare that only single myoma develops, they are usually multiple, discrete and 
spherical or irregular lobulated. (4)   
         On gross examination, in transverse section, the tumour is buff –colored, rounded, 
smooth and usually firm. Generally they are lighter in colour than the myometrium. (4) 
There is no true capsule to myomas; however the progressing borders produce 
compression of the surrounding tissues and production of the so-called pseudocapsule (16). 
It is a thin layer of areolar tissue and compressed muscle fibres, through which the blood 
vessels enter the myoma (17). This pseudocapsule is useful in delineating the margin of the 
tumour during surgical resection and it allows for the easy shelling out of the myomas 
from their uterine bed (14).  
         On microscopic examination myomas display a proliferation of mature smooth 
muscle cells arranged in a trabeculated or whorled configuration. The muscle fibers are 
arranged in interlacing bundles. Fibrous connective tissue extends between the muscle 
bundles and is proportional to the amount of atrophy and degeneration (16). The myocytes 
are of spindle  shaped muscle cells  (17) , with elongated nuclei remarkably uniform in size 
, and the nuclear  cytoplasm gives a characteristic benign appearance .At its periphery , 
the muscle fibres are arranged in concentric layers , and the normal muscle fibers 
surround the tumour are similarly oriented (17). 
         Myomas are originally located within the myometrium (intramural); however when 
noted clinically, they may be submucous, subserous, intraligamentous, pedunculated or 
parasitic (16).  
         Those tumours expanding toward the endometrial cavity and tend to compress the 
endometrium become submucous, or if further growth occurs, they may expand on a 
pedicle and eventually protrude from the cervical os becoming necrotic or infected (16).   
         Growth towards the peritoneal cavity produces the typical irregular contours noted 
clinically (16) .It may be just at the serosal surface of the uterus, or they can have a broad 
or pedunculated base, bulge outward from the myometrium. It may be intraligamintary i.e 
extending between the folds of the broad ligament (4).  
         If the pedicle of a pedunculated sub-serous fibroid twists gradually, the ischemic 
/partially necrotic mass may then be isolated by the omentum or the bowel mesentery, re-
establishing a blood supply and becoming so called parasitic leiomyoma (16).  
         The long term outcome of leiomyoma, like other tissues depends on the 
maintenance of vascular supply. As the entire blood supply of the myoma is derived from 
one or two arteries entering from the pseudocapsule, the growth of the tumour means that 
it often outstrips its blood supply. This lead to degeneration, particularly in the central 
portion of the myoma: hyaline, cystic, calcific, fatty and red degeneration have been 
described (17).  
Hyaline degeneration: 
         Is the most common and mildest form of degeneration, occurring in 60% of 
myomas. The smooth muscle cells are replaced by fibrous connective tissue. The cut 
surface no longer demonstrates the original whorled appearance. Histologically, the 
cellular detail is lost as replacement by fibrous tissues continues (16). 
Cystic degeneration: 
         Occurs when hyaline changes continue to affect the myoma. These tumours may 
become liquefied and form cavities filled with clear or gelatinous material. The change 
may be so severe that the myoma becomes a hollow cavity and develops the appearance 
of a cystic mass.  Cystic change occurs in approximately 2% of myomas (16).  
Fatty degeneration: 
         Is rare and results from severe hyaline degeneration. The presence of true fat in a 
myoma is uncommon; however, the degenerated myoma may develop a yellowish fatty 
appearance (16). 
Calcific degeneration: 
         Occurs in 4-10 % leiomyomas when calcium carbonate and phosphate are deposited 
in areas of necrosis .The calcification may be diffuse, solid or circumferential. Thompson 
and Rock refer to these tumours as "womb stones "in their extensive treatise on the 
subject of leiomyomas. These are seen on x-ray film incidentally in postmenopausal 
women (16). 
Carneous or red degeneration: 
         Occurs in rapidly growing myomas, e.g., during pregnancy. This may cause severe 
abdominal pain of a sudden onset and tenderness localised to an area of the uterus, 
associated with mild pyrexia and leucocytosis. The symptom and signs typically resolve 
over a few days and surgical intervention is rarely required. Degeneration is essentially 
an ischemic, necrotic degeneration caused by loss of blood supply, and the red color is 
secondary to thrombosis and extravasation of blood into the myometrium giving it a raw 
beef appearance (16). 
         Infections may occur in any myoma, but they occur more commonly in those with 
advanced degeneration or relapse. Thompson and Rock quote one case of clostridium 
tetani in a myoma. In severe cases of intramural necrosis and infection, frak peritonitis 
and sepsis may develop. However, these cases are rare (16). 
         Rarely malignant/sarcomatous changes may occur (4).  
         Many histlogic variations of myomas have been described:  cellular, atypical, 
epitheliod, lipoleiomyomas and leiomyoma with tubules (18). 
   
         Cellular leiomyomas are composed of small cells with scanty cytoplasm and may 
be confused with leiomyosarcomas (16).   
         Atypical leiomyomas contain atypical cell clusters distributed throughout the 
tumour(16) .There are uniform smooth muscle cells with a level of mitotic activity of 
between two and nine mitoses per ten high power field(HPF) (19). This variant is called a 
smooth muscle tumour of uncertain biological behaviour. Also called “bizarre” or 
“symplastic” and are also often confused with leiomyosarcomas (16). 
         The epitheliod variant is composed of plump eosinophilic tumour cells.  However, 
even when epitheliod leiomyoma has only low mitotic activity (two to four per 10 HPF) 
metastasis may occur (19). It includes leiomyoblastoma, clear cell leiomyoma, and 
plexiform leiomyoma as described by Kuman and Norries (20). Coagulative necrosis 
(rather than hyaline necrosis or infraction) in fibroid is a sinister feature associated with 
recurrence and metastasis (19). 
         Myxoid change is an extension of hyaline change, with mucinous material visible 
macroscopically on the cut surface of the fibroid, and produces a myxoid leiomyoma 
.Extensive myxoid change results in cystic change. When cystic change occurs rapidly it 
can be painful. These tumours behave like epitheliod leiomyosarcoma and tend to be 
aggressive (19). 
          Leiomyosarcomas have large areas of fat and are diffuse or circumscribed. 
Leiomyomas with tubules have epithelium-lined tubules and are uncommon. Mesothelial 
differentiation also occurs (16). 
         Intravenous leomyomatosis is a very rare condition in which benign smooth muscle 
cells grow into veins .The principle symptoms and signs are of abnormal bleeding per 
vaginum and dull abdominal pain.  Microscopically, tumour is seen in veins of diffuse 
sizes; arteries are not involved. All of the above subtypes of leiomyoma can for 
intravascular leiomyomatosis, and the prognosis is same for all types. Treatment is by 
hysterectomy and bilateral salpingo-ophorectomy and unexpectedly the prognosis is good 
even when the lesion has not been completely excised. It may extend as rubbery cards 
beyond the uterus into the parametrium or occasionally into the vena cava. Some patients 
may survive for prolonged periods in spite of incomplete resection of the disease (21). 
         Leiomymatosis peritonealis dissaminata is a condition in which numerous nodules 
of histologically benign smooth muscle are present on peritoneal surfaces. It is frequently 
associated with a term pregnancy or with the use of oral contraceptives, and regression 
may occur after termination of the pregnancy (21). 
PATHOPHYSIOLOGY: 
         The pathophysiology of leiomyomas is not well understood. A range of hypotheses 
according for the pathogenesis of fibroid has been explored. 
         The key features of uterine leiomyomata are their occurrence during reproductive 
years, where ovarian hormones levels are high, their diverse manifestations as either 
single or multiple tumours, and the existence of racial and familial predisposition (3). So 
genetic predisposition, steroid hormones, and growth factors are important factors in 
fibrotic processes and angiogenesis all play a role in the formation and growth of these 
tumors (22).   
         At least two distinct components contribute to leiomyoma development: 
- Transformation of normal myocytes into abnormal myocytes. 
- Growth of abnormal myocytes into clinically apparent tumours. 
   
   
 
         The first process appears to be quite common, in view of the high prevalence of 
microscopic myomas (23). The subsequent growth of the neoplasm occurs via clonal 
expansion from a single cell (24,25). 
         The possibility of abnormal oestrogen receptor expression has been explored and 
discounted; both main progesterone receptor subtypes are expressed similarly in myoma 
and normal myometrium. Thus myoma tissue is still influenced by ovarian hormones. 
Experimentally, progesterone has been shown to stimulate the production of both an 
apoptosis –inhibiting protein and epidermal growth factor (EGF) in cultured myoma 
tissue. Oestrodial has the effect of stimulating expression of EGF receptor (3). 
Growth factors: 
         Leiomyomas can be described as a fibrotic process manifested by up regulation of 
types 1 and 111 collagen , the major components of the extracellular matrix , that 
distinguish leiomyomas from the normal myometrium (24) . The angiogenic growth factor 
basic fibroblast growth factor (bFGF) and its receptor appear significantly altered in the 
leiomyomatous uterus as illustrated by the following observations: 
- There is more bFGF mRNA in leiomyomas than in normal myometrium (25). 
- The ectracellular matrix of myomas contains a large reservoir of bFGF (25). 
- There is abnormal expression of the type1 bFGF receptor in the myometrium of 
women with leiomyoma-related bleeding compared to normally cycling women (26). 
- bFGF stimulates proliferation of leiomyoma cells in culture. This process is 
inhibited by interferon-alpha, a factor known to block the action of bFGF in other 
systems (27). 
         Transforming  growth factor –beta (TGF-beta) and granulocyte-macrophage colony 
stimulating factor (GM-CSF) which are involved in other fibrotic processes, may also 
contribute to the pathophsiology of leiomyomas when obtained from the secretory phase 
of the menstrual cycle, leiomyomas appear to have higher levels of TGF-beta and TGF-
beta receptor  mRNA and protein than the myometrium (28). In addition, there is a 
substantial reduction in TGF-beta levels in the leiomyomas of women treated with a 
gonadotropin-releasing hormone GnRH-agonist to diminish the size of their tumors prior 
to surgical extirpation (27). 
         GM-CSF may differentially stimulate leiomyomas and normal myometrium both on 
its own and through an increase in expression of TGF-beta (29). A TGF-beta homologue , 
endometrial bleeding –associated factor (EBAF) , which is normally expressed in the 
endometrium only in the luteal phase of the menstrual cycle , is expressed throughout the 
cycle in women with abnormal uterine bleeding of various aetiologies , including 
leiomyomas (30). 
         Reduced expression of growth inhibitory factors such as monocyte chemotactic 
protein 1 (MCP-1) may play a part in the loss of inhibition required for fibroid growth. 
Treatment by ovarian suppression is associated with an increase in matrix 
metalloproteinase (MMP) expression and a decrease in metalloproteinase inhibitory 
activity, which suggest that ovarian hormones have a role in maintaining the architecture 
of a myoma once formed (3). 
GENETICS 
         Leiomyomas may be viewed as a common phenotype resulting from a number of 
different genetic events. There are a variety of specific karyotypic subgroups that 
characterize myomas; however, the evolution of a cytogenetic abnormality appears to be 
a late event (25). 
         Cytogenetic studies have identified specific features of uterine myoma tissue 
compared to normal myometrium and to leiomyosarcoma. It appears that cells within an 
individual myoma are monoclonal in origin, but cells from different myomas within the 
same uterus are of independent origin. It is likely that the clonal expansion of tumour 
cells precedes the development of cytogenetic aberrations, but the latter may determine 
the clinical course depending on the extent to which control over growth is lost. Some 
evidence for this is provided by cytogenetic analysis, which showed a greater proportion 
of karyotypic abnormality in larger, compared to smaller fibroids. The most common 
cytogenic aberrations have been detected on chromosome 12, 6, 3 and 7, a ring 
chromosome 1, and translocation involving chromosomes 12 and 14. Relevant areas of 
chromosomes 12, 6 and 7 are thought to contain putative growth-regulating or tumour-
suppressor genes (3).   
         One gene, high mobility group protein 1 C (HMG 1C), appears to be dysregulated 
in the subgroup of myomas characterized by acquired 12 q 14-15 rearrangements. 
Myomas with this abnormality tend to be larger than those with a normal karyotype (31). 
         It is not yet clear to what extent the cytogenetic features can be correlated with the 
clinical picture (3). 
         Twin studies and family studies imply a familial predisposition to leiomyomas (32). 
As example in Reed’s syndrome uterine fibroids are found in kindreds with subcutaneous 
leiomyomas, and in Bannayan-Zonana syndrome they occur with other benign 
mesenchymal tumours (e.g. lipomas, hemangiomas) (33_35). 
         The possibility of malignant transformation of a fibroid to a leiomyosarcoma has 
traditionally been cited as a reason to recommend surgery for fibroids, with a stated risk 
of up to 0.5 %. However, current opinion is that where a sarcoma develops in the 
presence of fibroids the association is coincidental, and that malignant transformation of 
a fibroid is unlikely .The cytogenetic evidence gives some basis for reassurance on this 
point as the typical findings in leiomyosarcoma tissue are of more extensive genetic 
instability, with frequent deletions especially involving chromosomes 1 and 10 (3). 
Vascular abnormalities: 
         Abnormalities in uterine blood vessels and angiogenetic growth factors also appear 
to play a role in pathology of myoma formation. The myomatous uterus has increased 
numbers of arterioles and venules, as well as venular ectasia (ie.dilation) (36). Molecular 
alterations leading to increased vessel number or abnormal function are the likely 
mechanisms for the abnormalities, although the venous changes were originally thought 
to be induced by physical compression of the vascular structures by bulky myomas (25).    
Clinical manifestations: 
         Most small myomata, and some larger ones, are symptomless and are only detected 
during a routine examination (17).It may be identified coincidentally, for example at the 
time of taking a cervical smear or performing laparoscopic sterilization (3). 
         The estimates of symptoms caused by uterine leimyomas range from 10 to 40 %. It 
is likely that the lower estimates more accurately reflect the incidence of symptoms due 
to the large number of known small asymptomatic myomas (16). 
         Symptoms from myomas depend upon their location, size, and state of preservation 
and whether or not the patient is pregnant (4). 
Increased uterine bleeding: 
         The most common symptom associated with leiomyoma is abnormal uterine 
bleeding, most oftenly menorrhagia defined as > 80cc blood loss over the course of a 
menstrual flow. Interestingly >50% of women reporting blood loss have measured blood 
loss that is within normal limits. Indeed, many women with even larger myomas may 
have regular menses of measurable duration and flow. Heavy bleeding does occur in 
approximately 30% of women with symptomatic bleeding presenting as both 
menorrhagia and metrorrhagia (16). 
         Abnormal bleeding is commonly thought to be associated with submucous or 
pedunculated myomas on the basis of either ulceration or necrosis. However, ulceration is 
rarely observed in hysterectomy specimens or at hysterectomy.  Indeed, a study by Rubin 
and Ford indicates that the incidence of submucous myomas (5%) is too low to explain 
the incidence of menorrhagia (37). Sehgal and Haskins indicate that the surface area of the 
endometrial cavity may increase greater than 10 times with large myomas (38).As noted 
previously, the areas involved with myomas may have increased estrogen receptors and 
be relatively hyperestrogenic, leading to over-lying endometrial hyperplasia. Also Farrer-
Brown et al, have noted alteration in vasculature in the areas of leiomyomas that may 
alter normal haemostatic mechanisms (39).   Thompson and Rock recommend endometrial 
sampling even for patients who have regular menstrual flow (40). 
         Blood loss occurring over a long period of time may result in anaemia, weakness, 
dyspnoea and even congestive heart failure which must be treated before surgery(1).    
Pelvic pressure and pain:  
         Myomas can occur as single or multiple tumors and range in size from microscopic 
to tens of centimetres. The size of the myomatus uterus is described in menstrual weeks , 
as with gravid uterus . A 20-weeks size myomatous uterus is not unusual; it is often 
associated with increasing girth and a sense of fullness similar to pregnancy (1). 
         Pelvic pain is a common reason cited for either myomectomy or hysterectomy; 
however myomas probably do not cause pain except in a few specific cases. Carneous 
degeneration or torsion, both of which may be caused by vascular ischemia, may cause 
pain or low grade fever, uterine tenderness on palpation, elevated white blood cells count, 
or peritoneal signs (16). The discomfort resulting from degenerated fibroids is self limited, 
lasting from days to a few weeks, and usually responds to nonsteroidal anti-inflammatory 
drugs. If acute pain is the sole indication for surgery, other disease processes, such as 
endometriosis and renal colic, should be carefully excluded (41). 
         Quite often the development of discomfort comes on insidiously and the symptoms 
are difficult for a patient to define .She may complain of pelvic pressure, congestion, 
bloating or a feeling of heaviness in the lower abdomen (41). 
         Tumors that become impacted within the bony pelvis may press on nerves and 
create pain radiating to the back or lower extremities. Backache is such a common 
general complaint that it is usually difficult to ascribe it specifically to myoma (4).  
         Pressure and obstructive symptoms may be reported in up to 30% of patient with 
uterine myoma. For example, uterine leiomyomas have purportedly caused urinary 
incontinence, and bulky myomas may cause frequency secondary to lack of adequate 
space for urinary bladder expansion. It is possible for an anterior myoma to impinge on 
the urinary bladder or the lower uterine segment or a cervical myoma to obstruct the 
urethra. Posterior myomas may press against the sigmoid, causing dyschezia and 
constipation (16). According to an (ACOG) American collage of obs & gyne technical 
Bulliten, complete urethral obstruction has not been reported, but we and others have 
observed significant hydronephrosis in the presence of massive leiomyomas placing 
pressure on the pelvic brim (42). Thompson and Rock report that this hydronephrosis is 
generally reversible if no parenchymal damage has occurred (40). No studies appear to be 
available regarding degree of obstruction and alteration in renal function of patients with 
large, obstructing myomas or reversibility of the pathology if the obstruction is removed 
(16). 
         Dyspareunia from cervical myomas proximate to the vagina is also common. It may 
be due to shortening and distortion of the vagina by fibroids low in the pelvis, or to 
adherent prolapsed tubes and ovaries in the pouch of Douglas, or to tender uterosacral 
ligaments associated with chronic cervicitis(1). 
         There is a substantially increased incidence of secondary dysmenorrhoea in women 
with uterine myomas (43). 
         Rapidly enlarging uterine neoplasms are often attributed to leiomyosarcomas, 
although most women with this finding do not have a sarcoma. This was illustrated in a 
study of 1332 women admitted to two community hospitals for hysterectomy for 
presumed uterine leiomyomas , the incidence of uterine sarcomas was extremely low 
(0.23 %). (44)  
          Among 321 women with a rapidly growing uterus by clinical or ultrasound 
examination, only one (0.27 %) had a sarcoma. Based upon these data, an increased risk 
of sarcoma among women with “rapidly growing” leiomyomas could not be substantial. 
However the diagnosis of a uterine sarcoma should be considered in postmenopausal 
women with a pelvic mass, abnormal bleeding, and pelvic pain in whom the incidence of 




Effects on reproduction : 
         The risk of infertility is increased when the endometrial cavity is distorted by 
submucous leiomyomas (46). It may result from mechanical obstruction or occlusion of 
the fallopian tubes and it may prevent implantation of a fertile ovum (3). 
         By comparison, the role of intramural leiomyomas in infertility is controversial; 
some studies suggest myomas are sources of infertility (47); while more recent reports 
from women undergoing in vitro fertilization suggest they play a role (48_50). One case 
control study compared 106 women who had laparoscopic removal of their myomas to 
106 women with unexplained infertility and no myomas. The delivery rate was highest 
among   the group treated with myomectomy 42, 12 and 25 %, respectively (51).  
         Leiomyomas do not interfere with ovulation, but have been associated with 
infertility and adverse pregnancy outcomes in some (52_54) but not all (55_56) reviews. 
         Buttram and Rieter reported only 2-4 % of myomectomies were performed for 
myomas in the absence of other factors for infertility, they reported a significant 
reduction in spontaneous abortions (41% vs. 19 %) after myomectomy (57).The obvious 
possibility for causation of spontaneous, recurrent abortion may be present in the 
leiomymomatous uterus including endometrial obstruction, sub mucous myomas causing 
interference with implantation, placentation, and so forth. In addition, myomas have been 
associated with prematurity and still birth but no causal effects have been noted (16). 
         A population-based study of 2065 women with hospital discharge records 
indicating the presence of fibroids reported pregnancy outcomes based on birth certificate 
data (53). Compared to controls, women with fibroids were more likely to have abruption 
placentae (OR 3.87), first trimester bleeding (OR 1.82), dysfunctional labour (OR 1.85), 
breech presentation (OR 3.98), and caesarean section (OR 6.39) (53). 
         Approximately one third of women experience fibroid growth in the first trimester; 
the remaining women have stable or reduced tumour size during pregnancy (58, 59). The 
risk of abruption appears to be related to the size and location of the myoma; it is 
substantially increased if the myoma is large (e.g. >or =6cm) or subjacent to the placental 
site (52, 53). Other pregnancy complications noted in largely observational literature 
include pain, premature labour, retained placenta, and premature rupture of membranes 
(54, 60). 
         After delivery, postpartum haemorrhage may occur due to inefficient uterine 
contractions (3). 
      Other less common complications of fibroid include: 
- Prolapse into the vagina resulting in ulceration or infection (61). 
- Polycythemia from autonomous production of erythropoietin (61).  
          Uterine myomas may undergo torsion, infarction and/or necrosis during 
pregnancy, causing the patient to present with acute abdominal pain. The outcome of 
these occurrences is usually favourable with conservative management. However, if 
surgical management is directed by continued pain, infection, or other factors, several 
authors have reported satisfactory outcomes without excessive pregnancy loss. Other 
pregnancy complications include placental entrapment, lower-uterine   segment or 
pelvic obstruction (16).  
         Physical examination may establish the diagnosis in >90% of cases .The finding 
of enlarged, mobile, firm, irregular mass continuous with the cervix, on bimanual 
examination is almost always diagnostic(16).  
Differential Diagnosis: Other causes of an abdominopelvic mass in a woman in the 
reproductive years need to be considered (3).  
         The uterus enlarged with fibroid is typically firm in contrast to that of a uterus 
enlarged with pregnancy (3). 
         An ovarian tumour, whether benign or malignant, primary or secondary, may 
enlarge to occupy the pelvis and be difficult clinically to differentiate from a uterine 
fibroid (3). 
         Leiomyosarcomas typically present with a history of a rapidly enlarging 
abdominopelvic mass. There may be less mobility of the uterus than expected with a 
fibroid and general signs of cachexia (3) 
Investigations: 
         Imaging techniques are useful when it is necessary to confirm the diagnosis or to 
improve localization of the myoma prior to surgery; routine radiologic assessment is  
not  required and does not improve outcome [American College of Obstetricians and 
Gynaecologists]. The various imaging modalities have the following advantages and 
Disadvantages(Cohen) (3). 
    - Transvaginal ultrasound has high sensitivity (95 to 100 percent) for detecting 
myomas in uteri less than 10 weeks' size. Localization of fibroids in larger uteri or when 
there are many tumors is limited 3). 
-   Sonohysterography improves characterization of the extent of invasion into the 
endometrial cavity by submucous myomas(3) . 
-   Hysterosalpingography is a good technique for defining the contour of the uterine 
cavity. It has poor ability to visualize the rest of the myometrium and can falsely 
identify an intramural fibroid impinging on the uterine cavity as a submucosal fibroid (3). 
     - Magnetic resonance imaging is the best modality for visualizing the size and 
location of all uterine myomas and can distinguish among leiomyomas, adenomyosis, 
and adenomyomas. It may also be useful in differentiating leiomyomas from 
leiomyosaromas (3).  
    - Radiology with plain pelvic radiograph may show the characteristic stippling of 
calcification in uterine fibroids. A soft tissue shadow can be visible in other films (such 
as excretion urography) and show indentations and pressure effects (19). 
Invasive diagnostic procedures: 
         Diagnostic laparoscopy may be the only way to resolve a differential diagnosis 
between adnexal pathology and small eccentric fibroids that may not warrant therapy(19). 
         Hysteroscopy is particularly important in the diagnosis of intracavitary projection 
of benign uterine tumors, whether of the myometrium or endometrium. This procedure 
may often be carried out at a one _stop diagnostic outpatient clinic (19). 
         Laparotomy may be the only way that distinction between uterine leiomyomas 
and adenomyomas can be made, and permits histological confirmation (19). 
Treatment of uterine lieomyomas 
 Both medical & surgical therapies are utilized in treatment of fibroids. 
Asymptomatic uterine lieomyomas are usually treated expectantly (62).                       
Factors that should be considered prior to initiating treatment include: 
_size of the myoma(S) 
_location of the myoma(s) 
_symptoms 
_woman's age (e.g., is she near menopause) 
_reproductive plans 
The type & timing of intervention should be individualized based upon the woman's 
discomfort, pregnancy plans & obstetrical history, and the likelihood of age or hormonal 
therapy-related progression of the neoplasms (63). 
Medical therapy: 
Benign tumors of the uterus, like the normal myometrium and endometrium 
from which they are derived, have oestrogen and progesterone receptors and 
are therefore open to attempts at hormonal manipulation (19). 
Gonadotropin-releasing hormone analogs: 
Gonadotropin-releasing hormone (GnRH) analogs are the mainstay of 
medical therapy of uterine myomas. These drugs work by initially increasing 
the release of goadotropins, followed by desensitization and down regulation 
to a hypogonadotropic, hypogonadal state clinically resembling menopause. 
Most women will develop amenorrhea and a significant reduction in uterine 
size with this therapy (64, 65).However, there is rapid resumption of menses 
and pretreatment uterine volume after discontinuation of the medication. In 
addition, significant symptoms can result from these severe hypoestrogenism 
that accompanies administration of GnRH-analogs (64).Bone loss leading to 
osteoporosis after long-term use is the most serious complication. For these 
reasons, GnRH-analogs are primarily employed to temporize or to help 
prepare a woman for surgery. As an example, a meta-analysis of 19 
randomized controlled trials found that GnRH analogs administered for three 
to four months prior to fibroid surgery reduced both uterine volume and 
fibroid size, helped to correct preoperative iron deficiency anemia, and 
lowered intraoperative blood loss (66).preoperatively administered GnRH –
analogs decrease blood loss at the time of surgery and increase the 
preoperative hematocrit when taken for two to three months before the 
procedure. (67).since oral iron supplementation alone will improve the 
preoperative hematocrit in significant number of patients, the cost and 
adverse effects of of GnRH agonists must be weighed against their efficacy. 
GnRH agonist therapy may not be cost effective in all women .In addition, 
this treatment may induce fibrous changes within the myoma capsule, thus 
making the lieomyoma difficult to remove .The drug has not been shown to 
increase the subsequent pregnancy rate or decrease adhesion formation. It is 
unclear whether the smaller uterine size that results from preoperative 
treatment allows more women to undergo myomectomy rather than 
hysterectomy (68_70). 
The issue of GnRH agonists used preoperatively prior to hysterectomy has 
been investigated by several  authors with relation to convertion from 
abdominal hysterectomy to vaginal hysterectomy,  convertion from mid line 
to Pfannenstiel incision, and therapy for preoperative anaemia and operative 
complications (16). 
Recurrence after GnRH treatment: 
Lieomyomas can occur after myomectomy. one randomized study found no 
difference in the rate of recurrent fibroids developing over 27 to 38 months in 
women treated with a GnRH agonist compared to those treated with 
progesterone before surgery (71).women who had at least four myomas removed 
were at greater risk of recurrence. However, other investigators have found an 
increased incidence of recurrent fibroids following GnRH agonist pretreatment 
(63 versus 13 percent) (72). 
 Other: 
Autologus blood donation may be indicated if intraoperative blood loss is 
likely greater than 500_1000 ml. In one series, twenty percent of women 
undergoing abdominal myomectomy required blood transfusion and 70% of 
these received autologus blood (73). 
GnRH analogs with add back therapy: 
The side effects of long term GnRH_analog administration can be 
minimized by giving add back therapy with an estrogen-progestin after the 
initial phase of down regulation Low dose estrogen_ progestin therapy 
(equivalent to 0.625 mg of conjugated estrogen) maintains amenorrhea and 
the reduction  in uterine volume while preventing significant hypo 
estrogenic side effects( e.g. osteoporosis, vasomotor symptoms) ( 74). 
Similar clinical results have been achieved with GnRH_ antagonists. The 
advantage of these medications is the rapid onset of clinical effects and 
absence of an agonist phase. The antiprogestin mifepristone (RU_486) 
reduces uterine volume comparable to that observed with GnRH_agonists, 
but maintains the estradiol concentration in the early follicular range (75). 
Danasol and gestrinone: 
Danasol is a 19_nortestosreone derivative with progestin like effects .Its 
mechanism of action includes inhibition of pituitary gonadotropin secretion, 
direct inhibition of endometriotic implant growth, and direct inhibition of 
ovarian enzymes responsible for estrogen production. Since it induces 
amenorrhea, Danazol may control anemia due to fibroid related 
menorrhagia.  
A second androgenic steroid, gestrinone, decreases myoma volume and 
induces amenorrhea in women with fibroids .An advantage of this drug is 
that there is a carry-over effect after it is discontinued. In one study, for 
example, uterine volume remained lower than pretreatment values at 18 
months after discontinuation of therapy in 89% of women treated for six 
months (76). 
Ineffective therapies: 
Medical treatments that are commonly prescribed but appear ineffective 
include progestational agents and nonsteroidal anti-inflammatory drugs  . 
However, they may be useful in women with coexisting problems. (e.g. 
Pain). (64, 77) 
Progestational agents: 
Many algorisms for the treatment of abnormal bleeding due to myomas 
suggest a trial of oral contraceptives pills (OCPs) or progestin therapy prior 
to proceeding to definitive therapy. There is no evidence to sugesset that 
these are effective therapies for myomas(64_ 65).    However, oligoovulation 
and endometrial atrophy induced by hormonal therapy may help to decrease 
overall bleeding. 
Nonsteroidal anti-inflammatory drugs: 
Non steroidal anti-inflammatory drugs (NSAIDs) and anti fibrinolytic 
agents, which are useful in the treatment of idiopathic menorrahgia, have not 
been extensively studied in leiomyoma related menorrhagia. NSAIDs do not 
appear to reduce blood loss in women with myomas) (77_78). 
Operative procedures: 
Surgery is the mainstay of therapy for leiomyomas .Hysterectomy is the 
definitive procedure, myomectomy by various techniques, endometrial 
ablation, and myolysis are alternative. 
The surgical approach to myomectomy is dependent upon the location of the 
myomas. Myomectomy can be performed by laprotomy, transvaginally, 
laproscopically, or hysteroscopically. The abdominal approach is the gold 
standard for women with intramural tumors, vaginal myomectomy is the 
most appropriate technique for prolapsed myomas, and hysteroscopic 
resection is the best choice for sub mucosal fibroids (79). 
Abdominal myomectomy: 
Myomectomy (resection of a myoma (s)) is an option for women who desire 
future pregnancies or otherwise wish to retain their uterus or improve 
pregnancy outcome after repetitive miscarriages. 
Abdominal myomectomy can be performed through a transverse or midline 
incision. Surgical principles are similar to those used for other gynecologic 
surgical and infertility procedures, meticulous hemostasis and avoidance of 
adhesiogenic materials (79). 
A transabdominal myomectomy is the treatment of choice when there are 
multiple myomas or the uterus is significantly enlarged. The operative time, 
blood loss, and hospital stay are comparable to abdominal hysterectomy 
(79_80).the risk of unplanned hysterectomy at the time of myomectomy is less 
than 1% for the experienced surgeons (62). 
Hemostasis: 
Blood loss during myomectomy correlates with preoperative uterine size, 
total weight of fibroids removed, and operating time (81).  
Myometrial injection of vasoconstrictors such as vasopressin (made by 
diluting 10 to 20 U in 40 to 50 ml normal saline) help to control hemostasis. 
In a randomized placebo controlled trial ,the use of vasopressin significantly 
reduced operative blood loss (225 versus 675 ml ) (82).Other techniques 
include using a tourniquet ( e.g. Penrose drain or catheter )(83),or a long 
vascular _type  clamp with rubbershods applied over the clamp's jaws ,( 84),to 
compress the uterine vasculature and infundibulopelvic ligaments. 
Pharmacologic vasoconstriction and mechanical vascular occlusion are 
similarly effective (81).Employing 
electro surgery or laser for making the uterine incisions(s) also help to 
minimize blood loss (85_89).  
Reduction of adhesion formation: 
A posterior uterine incision should be avoided, if possible, because it is more 
likely to lead to postoperative adhesions. Copious irrigation with heparinized 
Ringer's lactate solution and moistened laprotomy packs may help to limit 
adhesion formation, placing these packs inside plastic packs reduces lint 
deposition. Adhesion prevention solutions (90) or application of adhesive 
barriers (e.g.Interceed, Gore-Tex) may be considered, but improvement in 
pregnancy rate is not certain (91). 
Uterine incision and myomectomy: 
The initial uterine incision should be large enough to allow removal of the 
maximum number of the number of incisions required. A vertical incision on 
the anterior uterine surface avoids the most vascular areas of the uterus. The 
incision is carried down to incise the myoma itself, this allows for 
identification of the plane between the myoma capsule and the myometrium. 
An Allis clamp or towel clip is placed on the myoma and traction is applied 
to help develop a plane between the myoma capsule and the myometrium 
using blunt and sharp dissection. 
Any loose connective tissue or vascular tissue between the capsule and 
myometrium is identified and the remaining connective tissue and blood 
supply are clamped and ligated. Electro surgery is used to desiccate any 
bleeding vessels. Every effort should be made to identify and remove all of 
the myomas (92).Most myomas can be identified by preoperative ultrasound 
and intraoperative visualization and palpation. Entry into the endometrial 
cavity should be avoided as this could lead to adhesion formation (e.g. 
ASherman's syndrome) or possibly result in uterine rupture with future 
pregnancy. Special care must be taken to avoid injury to the fallopian tubes 
during removal of cornual myomas.  
The myometrial defect is closed with several layers of interrupted sutures of 
delayed absorbable material or a continuous suture in concentric circles. The 
serosa is reapproximated using a baseball type or subserosal suture (93). 
Outcome: 
A review of abdominal myomectomy in 128 women reported an average 
intraoperative blood loss of 342 ml, with five patients sustaining blood loss 
greater than 1.000 ml (73).Hysterectomy was required in only one woman. 
Febrile morbidity occurred in 12 women. 
Although myomectomy is an effective therapy for menorrhagia and pelvic 
pressure, the disadvantages of this procedure is the significant risk that more 
leiomyomas will develop from new clones of abnormal myocytes .Five years 
after myomectomy, approximately 50% of patients will have myomas 
detected by ultrasound (94) and 11 to 26 %will require a second surgery after 
the first myomectomy. (95_97). The risk of uterine rupture after myomectomy 
prior to labor is very low (about 0.002%) compared to classical cesarean 
section, although these data are based upon a small series without complete 
pregnancy follow up. The common clinical practice of counseling women 
who have had a myomectomy with a transmural uterine incision to undergo 
an elective cesarean section clearly biases the reported risk of rupture at 
term. It is important to judge new surgical alternatives to abdominal 
myomectomy according to their safety for women whose aim is future 
pregnancy (98_99). 
Vaginal myomectomy: 
Prophylactic antibiotics are generally recommended although data from 
randomized studies are not available. The pedicle of a prolapsed fibroid can 
be clamped across the base, cut, and sutured ligated using a delayed 
absorbable suture material. This is not always possible with large myomas; 
these tumors must be morcellated until the base can be identified. 
Alternatively, a prettied surgical loop may be passed over the myoma and 
the base ligated .A Foley catheter placed into endometrial cavity and inflated 
can be used to tamponade excessive bleeding. 
Sub mucous myomas that are not prolapsed require cervical dilatation (e.g. 
with laminaria tents or cervical dilators). The myomas are then removed by 
grasping them with uterine polyp forceps or uterine dressing forceps. A 
diagnostic hysteroscopy should be performed after removal to determine 
whether other submucous myomas are present. Hysteroscopic resection of 
additional tumors can be performed if the patient is stable (100). 
Outcome: 
The procedure is successful in greater than 90%of cases (101).Morbidity 
following vaginal myomectomy is lower than with the abdominal approach. 
A second vaginal myomectomy becomes necessary in approximately 9%of 
women over a five year follow up period; approximately 6% require 
hysterectomy (102). 
Laparoscopic myomectomy: 
Women with a uterus less than 17 weeks size or with a small number of 
subserosal or intramural fibroids can consider the option of laparoscopic 
myomectomy (LM).The uterus must be small enough to allow visualization 
of the procedure through an endoscope placed at the umbilicus. Most 
authorities suggest limiting this procedure to the removal of three or fewer 
myomas and myomas not larger than 13 cm in diameter because this 
technique can take longer than open myomectomy, especially when 
laparoscopic suturing is employed. An electronic morcellator permits 
efficient removal of a large myoma in pieces through a small incision. 
Pretreatment with GnRH agonists 
reduced blood loss and operating time in some (103) but: not all studies (70). 
Outcome: 
Several prospective randomized trials reported that the early outcomes of 
laparoscopic and abdominal myomectomy are similar. Laparoscopic 
procedures, however, are associated with less postoperative pain and a 
shorter recovery time (104). 
Whether reappoximation of the myometrium via laparoscopic suturing gives 
the uterine wall the same strength as multilayer closure at laparotomy is an 
area of controversy(105),The authors of case reports describing uterine rupture 
after LM as early as 33 or 34 weeks of gestation have suggested that women 
with intramural fibroids undergo laparotomy or modified laparoscopic 
closure. By comparison, one series of 100 deliveries  after LM reported three 
cases of spontaneous uterine rupture ,only one of which occurred in the LM 
scar. No uterine rupture occurred among the 72 patients who had a trial of 
labor. Until further data are available, laparoscopic myomectomy, especially 
when there is a deep intramural fibroid, should be used with caution in 
women whose primary goal is to achieve a pregnancy (106_107).  . 
Laparoscopic myolysis: 
A neodymium: yttrium aluminum gamet (Nd: YAG) laser can be used to 
coagulate and devascularise myomas through the laparoscope. This method 
involves pretreatment of women with a GnRH agonist for tow to six months. 
Ten percent vasopressin solution is injected directly into the serosa of 
myomas. The Nd: YAG laser is set at 50 watts of power using 600 mm fiber. 
The bare fiber is used to pierce the myoma in multiple places at 5 mm 
intervals, thus, 75 to 100 puncture are used for a myoma measuring 5 cm. 
Myomas regress by 50_90% of their original volume over the three to six 
months following the procedure. Recurrences are infrequent, however, dense 
and fibrous adhesions can occur, thus, until additional data are collected; this 
procedure is only recommended for women who do not desire further child, 
but bearing who want to retain their uterus (108 _109). 
Hysteroscopic resection: 
The ideal myoma for hysteroscopic removal is a pedunculated submucous 
myoma.A continuous flow hysteroscope allows optimal visualization 
because any bleeding can be easily cleared .The uterine cavity is distended 
with either a high-viscosity (e.g.,Hyskon )or a low viscosity ( e.g.,4% 
sorbitol) fluid media infused by gravity ,although an electronic pump can be 
used .The tumor is gradually removed be applying a" shaving" technique 
through the resectoscope. Laparoscopy is performed routinely by some 
authors and must be done if there is any significant degree of intramural 
extension(109_110). 
The submucous location of these tumors offers ready access to an operative 
endoscope placed through the cervix. Although this technique requires 
highly skilled practitioners, it has several advantages compared to abdominal 
procedures: 
 - It is performed as same day surgery. 
 - Local anaesthetic and sedation can be use                                                                               
 - The recuperation period is short. 
 - Good relief of symptoms is obtained .In one large series ,fewer than 16% 
of women treated for menorrhagia underwent a second surgery in the nine 
year follow - up period (111) . 
Fertility rates are excellent and there have been no case reports of uterine 
rupture after hysteroscopic myomectomy (112). 
Pedunculated leiomyomas: 
Pendculated myomas are cut near the pedicle base by positioning a wire loop 
behind the myoma and cutting the stalk with an electrosurgical (or laser) 
energy source. A pure cutting current is used to avoid having tissue stick on 
the loop itself .Special care should be taken to avoid disturbing the 
endometrium and surrounding myometrium. 
The myoma is removed intact or after morcellation using a polyp forceps. 
Portions of the fibroid that can not be removed may be left inside the uterus 
and will undergo degeneration over a tow to three week period (113). 
Sessile leiomyomas: 
Removal of sessile myomas embedded within the myometrium generally requires 
both hysteroscopy and laparoscopy. The intramural portion is removed by shaving 
the tumor with the resectoscope loop; while the laproscopist ascertain that the 
uterus is not being perforated . 
Hysteroscopic resection should not be attempted if the myoma extends 
greater than 50% into the myometrial wall (113). 
Complications: 
The most serious complication of hysteroscopic myomectomy is fluid 
overload, which can result in pulmonary edema, electrolyte disturbances and 
death. Fluid absorption should be calculated closely, as with all 
hysteroscopic surgery. Other potential complications include bleeding and 
uterine perforation (113). 
Outcome: 
Outcome after hysteroscopic resection is variable and depends upon the type 
of myoma and desired result. In one series of 108 women who underwent 
primary hysteroscopic removal of peduncuated, sessile and intramural 
myomas the myomas recurred in 27 subjects and 20 women had recurrent 
menorrhagia after a mean follow-up period of 41 months. The three year 
cumulative probability of conception in women with pedunculated, sessile 
and intramural lesions was49, 36, and33 percent respectively (114). 
Endometrial ablation: 
Endometrial ablation either alone or in combination with hysteroscopic 
myomectomy, may alleviate bleeding with minimal invasiveness in women 
with uterine leiomyomas who have completed childbearing. Although most 
case series of endometrial ablation have excluded women with significant 
myomas, one study that examined endometrial ablation with hysteroscopic 
myomectomy reported only an 8% risk for a second surgery after a mean of 
six year follow-up (111). 
Myolysis: 
Myolysis refers to laparoscopic coagulation of leiomyoma tissue (115).This 
technique is easier to master than resection which requires suturing. 
However, localized tissue destruction without repair may increase the 
chance of subsequent adhesion formation or rupture during pregnancy (116). 
Myolysis combined with endometrial ablation is a more effective therapy 
than either procedure alone. A descriptive study that compared ablation 
alone with the combined procedures in women with menorrhagia found that 
the risk of a second surgery was 38 and 13 percent respectively (117). 
Uterine artery embolization:   
Uterine artery embolization (UAE) is an innovative technique based upon 
the hypothesis that control of myometrial arterial blood flow will control 
symptoms (118_120). One study found the technique was useful in controlling 
leiomyoma-related menorrhagia in approximately 90 percent of patients 
and pressure symptoms in 91 percent at 1 year after treatment; 10 percent 
required surgical intervention during the follow-up period (30). The mean 
reduction in uterine volume appears to be 40 to 60 percent (121_122, 30).  
However, mean volume reduction may be lower in women with only 
intramural myomas since submucous myomas are likely to be expelled 
vaginally after UAE and submucosal location is a strong predictor of 
volume reduction (122,123_125). 
Other  – Regulation of growth factor pathways is another area of innovative 
treatment. There is evidence that interferons can reverse the proliferative 
effects of bFGF on leiomyoma cells in culture (126). As an example, a 
woman undergoing treatment with interferon-alfa for hepatitis C had 
dramatic and sustained shrinkage of a uterine leiomyoma after seven 
months of therapy (127). 
Pregnancy:  
Uterine leiomyomas occur in approximately two percent of pregnant 
women and usually do not interfere with the course of pregnancy (128_129). 
Myomectomy during pregnancy should be avoided, if possible, because of 
the risk for intraoperative hemorrhage and subsequent pregnancy loss 
(130_131). The procedure may be considered for symptomatic myomas that 
do not respond to conservative therapy, especially if the myoma is 
pedunculated and readily resectable (132-133) 
 Disadvantages of myomectomy                                                         
 Although myomectomy is an effective therapy for menorrhagia and pelvic 
pressure, the disadvantage of this procedure is the significant risk that more 
leiomyomas will develop from new clones of abnormal myocytes. Five 
years after myomectomy, approximately 50 percent of patients will have 
myomas detected by ultrasound (134), and 11 to 26 percent will require a 
second surgery after the first myomectomy (135_137).                                                                                                        
 Hysterectomy:  
Hysterectomy eliminates both current symptoms and the chance of 
recurrent problems from fibroids. For many women who have completed 
childbearing, this freedom from future problems provides an attractive 
option (63). As an example, a two year follow-up study of 1299 women who 
had undergone hysterectomy for benign conditions found that more than 90 
percent noted significant reductions in symptom severity, depression, and 
anxiety levels, and an improvement in quality of life (13). 
Hysterectomy may be performed either with or without oopherectomy 
without apparent sequelae with reference to  myomas (13). 
Patients with symptomatic uteri should be offered a trial of conservative 
management prior to hysterectomy. Symptoms of excessive uterine 
bleeding lasting longer than 8 days or bleeding either acutely or chronically 
to the point of anaemia are considered adequate indications for surgery .In 
addition, acute or severe abdominal pain, chronic abdominal or back pain, 
or pressure on contiguous organs to the point of discomfort is considered an 
adequate indication for operative intervention (16). 
The procedure may be performed via a midline or Pfannenstiel incision, 
depending on the patient’s body habitus, skeletal configuration, and the 
size and configuration of the uterine myomas. The same techniques are 
performed during hysterectomy for other reasons should be followed in 
the performance of hysterectomy for myomas (16). 
Future Directions : 
The biology of uterine fibroids has traditionally been explained in terms of 
steroid hormones; thus, all current medical therapies are based upon 
manipulation of these hormones. However, an expanded view of the 
biology of this benign tumor (e.g., the specific genes that are deregulated) 
may open new avenues of pharmaceutical intervention and ultimately lead 






























1- To find out factors which affect the type of operation done 




2- To assess the range of complications and outcome associated 












































Patients and methods: 
 
Study design: 
A descriptive prospective, cross sectional, hospital based study. 
Study period: 
The study was carried out in the period from 15th of September 2004 to the 
15th of March 2005. 
Study area: 
The study was conducted in three maternity units in three hospitals in 
Khartoum state:  
1. Ribat University Hospital; the major hospital of police force in Sudan. 
2. The Academy charity hospital in Alsahafa area; where medical students of 
The Academy of medical sciences receive their clinical training. 
3. Soba university hospital; the major hospital where Khartoum University 
supervises training of medical students and registrars. 
Study population: 
One hundred and fourteen women with uterine fibroids presented to the 
three hospitals where the study was carried out during the study period, were 
selected. 
From the total 77 women had myomectomy and 37 women had abdominal 
hysterectomy as the modality of treatment. Patients were selected to the 
study after giving an informed concent. The type of treatment was decided 
by the treating doctor without previous knowledge of the study participation. 
Data collection: 
Data was collected by direct interview of the patients using questionnaire 
containing information about personal data, parity and present history of the 
patient. 
Information about size, site and number of the fibroids in addition to the 
intraoperative findings and postoperative complications were collected from 
the treating doctor's records. 
Data analysis: 
The data was analyzed using the computer statistical programme SPSS and 
presented in tables and figures. The P_value at 85% confidence interval was 






























































































Age group Total 












14(12.30%)86(75.40%)14     
















Total Widow/DivorcedMarried Single 






























































Type of operation  
   77
(100.0%)
       4 
(5.2%) 
    17
(22.1%)
    56
(72.7%)       
       
Myomectomy 
   37
(100.0%)
        12 
(32.4%) 
     17
(45.9%)  





    16 
(14.0%)    
    34
(29.8%)






























Table 4  
 
Type of operation and size of fibroid 
 
 
               Size of fibroid Total





     77
(100.0%)
     16 
(20.8%) 
     32
(41.1%)
    29
(37.7%)
Myomectomy 
     37
(100.0%)
       8 
(21.6%) 
     15
(40.5%)




     114
(100.0%)
        24 
(21.1%) 
     47
(41.2%)



































Table 5  
 




            Number of the fibroids  Total
  > 5   2_5 Single
Type of 
operation 
     77
(100.0%)
    15 
  (19.5%) 
   35
(45.5%)
      27
(35.1%)
Myomectomy 
     37
(100.0%)
     14 
(37.8%) 
    6
(16.2%)




     114
(100.0%)

















































      77
(100.0%)
       11 
(14.3%) 
   42
(54.5%)
    24
(31.2%)
Myomectomy 
      37
(100.0%)
       9 
(24.3%) 
   16
(43.2%)




     114
(100.0%)
       20 
(17.5%) 
   58
(50.9%)











































Site of fibroid 









   58
(100.0%)
  11 
(19.0%) 
  11




    20
(100.0%)














































                            Fertility              Total
            No           Yes










   26
(63.4%)





   12
(85.7%)
   2 
(14.3%)
Submucous 
   78
(100.0%)
    51
(65.4%)







































   Hemoglobin concentration Total
Mean Postoperative 
Hb      
Mean  Preoperative 
Hb



































Table 10  
 



















                 Need for transfusion   Total 
 > 2 pints 1_2 pintsNo need
Type of operation 
    77 
(100.0%) 







    37 
(100.0%) 








  114 
(100.0%) 
   20 
(17.5%)





















Type of operation and duration of hospital stay 
 
 
  Duration of hospital stay     Total
   > 7 days  4_7 days
Type of operation
        77
(100.0%)
     39 
(50.6%) 
    38
(49.4%)
Myomectomy
        37
(100.0%)
    27 
(73.0%) 




       114
(100.0%)




































Type of operation and postoperative complications 
 







   77
(100.0%)
     1 
(1.3%) 
   1
(1.3%)
     2
(2.6%)
    73
(94.8%)
Myomectomy 
   37
(100.0%)
      1 
(2.7%) 
   0
( 0.0%)
    5
(13.5%)






     2 
(1.8%) 
    1
( 0.9%)
     7
(6.1%)


































































































































































































































































































 Figure 6 
 











































Out of one hundred and fourteen women with uterine fibroids included in 
the study 77 women (67.5%) had myomectomy as the modality of treatment 
while 37 women (32.5%) had abdominal hysterectomy. Figure 1. 
Of the women  treated with myomectomy18.2%(14 women )  were less than 
30 years old while no woman with abdominal hysterectomy was in that age 
group  .79.2% (61)of  women who were treated by myomectomy were 
between 30 to 45 years compared to 25 women (67.5%) of women with 
abdominal hysterectomy. Two women with myomectomy (2.6%) were more 
than 45 years old compared to 12 women (32.4%) with abdominal 
hysterectomy .Table 1 
Comparing women treated with myomectomy to those treated with 
abdominal hysterectomy, 33 women with myomectomy (42.9%) were single 
women compared to 3 women with abdominal hysterectomy (8.1%). 39 
married women (50.6%) had myomectomy while 27(73.0%) married women 
had abdominal hysterectomy. Five women (6.5%) with myomectomy and 7 
women (18.9%) with abdominal hysterectomy were widows or divorced 
women. Table 2. 
Table 3 shows the comparison between hysterectomy and myomectomy in 
regards to parity.56 women with myomectomy (72.7%) were nulliparous 
compared to 8 women (21.6%) with abdominal hysterectomy.17 women 
(22.1%) with myomectomy and 17 (45.9%) with hysterectomy had 1 _ 4 
children .Women with more than 4 children were 4(5.2%) treated with 
myomectomy compared to   12 women (32.4%) treated with abdominal 
hysterectomy. Table 3.  
Out of the whole population, It was found that 27 women (23.7%) were 
infertile compare to 51 fertile women (44.7%).Single women were 36 
comprising 31.6% of population. Figure2. 
Looking at the duration of infertility in the infertile population. Less than 2 
years infertility was found in 5.3% of women (6 women) while 11 women 
(9.6%) had infertility for 2 to 5 years. More than 5 years infertility was 
found in 10 of all women studied (8.8%).Figure 3. 
Figure 4 describes the presenting symptoms in the population. 
Asymptomatic women were 58 woman comprising 50.9% of population, 
women with menstrual disorders were 29 women (25.9%) and those with 
pressure symptoms were 27 women (23.7%) of all women. Fig 4. 
Considering past obstetrics and gynaecological history it was found that 99 
of all women in the study (86.8%) had no past obstetrics or gynaecological 
history, 13 women (11.4%) had past history of myomectomy while 2 women 
(1.8%) had past history of caesarean section. Figure 5.   
The size of the fibroids was less than 12 weeks in 29 women with 
myomectomy (37.7%) and in 14 women (37.8%) with abdominal 
hysterectomy. 32 women with myomectomy (41.1%) had fibroids ranging 
between 12 to 16 weeks compared to 15 women (40.5%) with abdominal 
hysterectomy. More than 16weeks fibroids were found in 16 women 
(20.8%) with myomectomy and in 8 women (21.6%) with abdominal 
hysterectomy .Table 4. 
Single fibroid was found in 27 women (35.1%) with myomectomy and in 17 
(45.9%) of those with abdominal hysterectomy. Two to five fibroids were 
found in 35 (45.5%) women with myomectomy compared to 6 women 
(16.2%) with abdominal hysterectomy. More than 5 fibroids were found in 
15 women (19.5%) with myomectomy and in 14 women (37.8%) with 
abdominal hysterectomy. Table 5. 
Comparing momentum with abdominal hysterectomy it was found that of 
the women treated by myomectomy, 24 women (31.2%) had subserous 
fibroids, 42 women (54.5%) had intramural fibroids and 11 women (14.3%) 
had submucous fibroids. In comparison 12 women with abdominal 
hysterectomy (32.4%) had subserous fibroids, 16 (43.2%) women had 
intramural fibroids and 9 women (24.3%) had submucous fibroids. Table 6. 
Table 7 shows the site of fibroids in relation to the presenting symptoms. It 
was found that 19 women (52.8%) with subserous fibroids were 
asymptomatic compared to 36 women (62.1%) with intramural fibroids and 
3 women (5.2%) of those with submucous fibroids. Menstrual disorders 
occurred mostly in women (15) with submucous fibroids (75.0%)   , in 11 
women (19.0%) with intramural fibroids and in 3 women (8.3%) with 
subserous fibroids. While pressure symptoms occurred mostly (38.9%) with 
subsrous fibroids (14 women),in11 women (19.0% )with intramural fibroids 
and in 2 women(10.0%) of those with submucous fibroids. 
When considering the site of the fibroids in relation to fertility status it was 
found that 2 women(14.3%)with submucous fibroids were infertile 
compared to15 women with intramural fibroids (36.6%). In fertile women 
10 had sub serous fibroids (43.5%). 13 of the  fertile women had subserous 
fibroids (56.5%),26 (63.4%) had intramural fibroids and 12 women 
(85.7%)had submucous fibroids. Table 8. 
There was more intraoperative blood loss associated with abdominal 
hysterectomy than with myomectomy. Table 9. The mean preoperative Hb 
concentration was 74.63% in women with myomectomy compared to 
78.90% in those with abdominal hysterectomy. In comparison, the mean 
postoperative Hb concentration was 67.90% in myomectomy and 71.36% in 
hysterectomy. There was a difference in preoperative and postoperative Hb 
concentration of 6.72% in women with myomectomy compared to 7.54% in 
those with hysterectomy.Table 9.  
Type of anaesthesia used for operation was general anaesthesia in 97 women 
comprising 85.1% of population while in the remaining 17 women (14.9%) 
spinal anaesthesia was used .Figure 6. 
Forty-four women with myomectomy (57.1%) did not need blood 
transfusion compared to 17 women (45.9%) with abdominal 
hysterectomy.21(27.3%)women with myomectomy and 12 (32.4%)women 
with abdominal hysterectomy received 1to2 pints of blood while 12 women 
(15.6%) with myomectoy and 8 (21.6%) with abdominal hysterectomy 
received more than 2 pints of blood. Table10. 
Duration of hospital stay ranged between 4 to 7 days in 38 women (49.4%) 
with myomectomy and more than 7 days in 39 women (50.6%).Of women 
treated by abdominal hysterectomy, 10 women (27.0%) stayed in hospital 
for 4 to 7 days, while 27 women (73.0%) stayed more than one week. Table 
11.   
No postoperative complications occurred in 73 women (94.8%) of women 
with myomectomy and in 31 women (83.8%) with abdominal hysterectomy. 
Two women treated by myomectomy had fever, one woman (1.3%) had 
abdominal pain and one woman (1.3%) had bleeding postoperatively. In 
comparison 5 women (13.5%) treated by abdominal hysterectomy had fever, 
no woman had abdominal pain and one woman (2.7%) had bleeding. Table 











































         One hundred and fourteen women with uterine fibroids who presented 
to the three hospitals where the study was carried out were included in this 
study. The modality of treatment applied to them was studied comparing 
myomectomy to abdominal hysterectomy. 
         In this study myomectomy was the commonest used modality of 
treatment (67.5%). 
         The majority of women (75.4%) were between 30 to 45 years old. 
Compared to the literature, fibroids were found in 20% to 25% of women 
aged over 35years (2). It was found that abdominal hysterectomy was more 
common in women over 45 years while myomectomy was common in those 
less than 30 years. This may reflect the fact that women more than 45 years 
usually had completed their families and had no desire for more 
childbearing. Vessey MP found that hysterectomy generally tended to 
increase with age  (133).IN a study done by Iverson et al it was found that 
there were significant differences between the two groups for average age 
(hysterectomy 39.2 years, myomectomy 34.4 years; mean difference 4.8, 
95% confidence interval [CI] of difference 3.7-5.9) (80). 
         Hillis et al   found that myomectomy is the first option for women who 
desire future pregnancies or otherwise wish to retain their uterus or improve 
pregnancy outcome after repetitive miscarriages (79).  
         In this study, comparing women treated with myomectomy to those 
treated with abdominal hysterectomy it was found that 42.9% of women 
with myomectomy were single women compared to 8.1% of women with 
abdominal hysterectomy. This may be in part due to the more conservative 
approach of management applied to single women in our community. This 
may  also be  applied to married women :  39 women( 34.2% of  population 
) were married and were  treated with myomectomy  compared to 27 married 
women( 23.7% of population ) treated with abdominal hysterectomy. Marital 
status per se dose not seem to affect the decision of myomectomy or 
abdominal hysterectomy. It is the future fertility plans which affect such a 
decision. The reverse is true for widows and divorced women where 
hysterectomy was the most commonly used type of management (used in 
18.9% of women compared to 6.5% for myomectomy). 
         Hysterectomy eliminates both current symptoms and the chance of 
recurrent problems from fibroids. For many women who have completed 
childbearing, this freedom from future problems provides an attractive 
option (134).     
         It was found that the majority (56.1%) of women included in the 
study were nulliparous while 43.9% of them are parous women. This is 
consistent with the concept that parity (having one or more pregnancies 
extending beyond 20 weeks) decreases the chance of fibroid formation 
(7_9). 
         In this study 87.5% of nulliparous women were treated with   
myomectomy while the rest of them had hysterectomy.    Women with more 
than four children had hysterectomy (75% of them) more than myomectomy 
(25%). This may also support the above mentioned concept of conservative 
management for women who wish to preserve child bearing potential or 
enhance it.      
         Fertile women were noticed to be more in the whole population 
(44.7%) compared to infertile ones (23.7%).Single women comprise 
31.6% of population .These were not included in the fertility analysis.  
         As mentioned in the literature it is estimated that infertility is the 
major presenting secondary feature in around 27% of women with 
fibroid. The mechanism whereby fibroid adversely affect conception is 
unclear, but it is likely to be mechanical by virtue of cornual occlusion or 
by distortion of the cavity, preventing implantation (140)  
         In this study when site of the fibroids was analyzed in connection 
with the fertility status, it was found that 55.6% of infertile women had 
intramural fibroids compared to 7.4% with submucous fibroids and 37% 
with subserous fibroids. It is mentioned in the literature that the role of 
intramural leiomyomas in infertility is controversial; some studies 
suggest myomas are sources of infertility (47); while more recent reports 
from women undergoing in vitro fertilization suggest they play a role 
(48_50). 
          Garcia et al founded that the risk of infertility is increased when 
the endometrial cavity is distorted by submucous leiomyomas (46).  It may 
result from mechanical obstruction or occlusion of the fallopian tubes and 
it may prevent implantation of a fertile ovum (3).   
         Considering the past obstetric and gynecological history it was 
found that 11.4% of all women had past history of myomectomy.  This 
may reflect the recurrence rate of fibroids. In one study the recurrence 
rate of fibroid was 15%.Overall 10% of the women required further 
pelvic surgery, usually hysterectomy for recurrent or continuing 
symptoms following myomectomy. (136)  
 
          In another study the 10 years recurrence rate was as high as 27%, 
the outcome being more favourable for those who achieved a pregnancy 
compared with those who did not (137).    
         This different recurrence rate in these studies may be due to the 
difference in the duration of follow up.    
             Regarding the presenting symptoms it was found that 50.9% of 
women were asymptomatic. This is consistent with what is mentioned in the 
literature that most small myomata, and some larger ones, are symptomless 
and are only detected during a routine examination (7) and that uterine 
fibroids, which eventually develop in more than 50% of women, are usually 
asymptomatic (138).  
             Menstrual disorders occurred in 25.4% of the study population.  
Compared to literature, it is mentioned that the most common symptom 
associated with leiomyoma is abnormal uterine bleeding (16).  
            In this study pressure symptoms occurred in 23.7% of study 
population.  This is close to what was mentioned in the literature, that 
pressure symptoms may be reported in up to 30% of patient with uterine 
myoma (16).   
       When considering the site of the fibroids in regards to the presenting 
symptoms it was found that there is significantly more menstrual disorders 
associated with submucous fibroids (75.0%) compared to subserous and 
intramural fibroids and more pressure symptoms associated with subserous 
fibroids (38.9%).  
              
         Women with large fibroids of more than 16 weeks uterine size were 
treated with abdominal hysterectomy (21.6%) more than with 
myomectomy (20.8%). This may be due to the fear of massive blood loss 
associated with large or multiple fibroids. This finding is consistent with 
Iverson et al study where the mean fundal height in patients who 
underwent hyterectomy was 15.2 weeks compared to 11.5 weeks for 
myomectomy (80).   
          There was no difference between myomectomy and hysterectomy 
regarding treatment of women with small fibroids of less than 12 weeks 
size. 
        As mentioned in the literature, it is rare that only single 
myoma develops, they are usually multiple and that they may be very 
numerous (4).In this study single fibroid was found in 38.6% of all women, 
while  61.4% had more than one fibroid .   
         Abdominal hysterectomy was associated with more intraoperative 
blood loss compared to Myomectomy. This is evident by the more decrease 
in the mean postoperative Hb in the former (7.54% vs. 6.73%). 
         Blood transfusion was more in women treated with hysterectomy than 
those with myomectomy. 42.9% of women with myomectomy and 54% of 
women with abdominal hysterectomy received blood transfusion. These 
results were consistent with the study done by Iverson et al; they estimated a 
blood loss of 796 ml associated with abdominal hysterectomy compared to 
464 ml in myomectomy (80). 
       The higher transfusion rate associated with hysterectomy may be due to 
more experience in doing myomectomy than hysterectomy especially by the 
junior staff.  
        Duration of hospital stay ranged between 4 to 7 days in 49.4% of 
women with myomectomy and in 27.0% of women treated by abdominal 
hysterectomy.While50.6%.Of women treated by myomectomy and 73.0% of 
those with abdominal hysterectomy stayed in hospital for more than one 
week. This long hospital stay compared to Hutchins Study (2 to 3 days) may 
be attributed to the fact that in our hospitals as general we tend to keep 
patients with major surgeries for five days or more due to the use of midline 
longitudinal incision and closure with interrupted silk stitches. (139).   
         The overall complication rate was 8.2% of population. Women with 
myomectomy had more postoperative complications (94.8% of them) than 
those with abdominal hysterectomy (83.8% of them). Extensive tissue 


























      Fibroids are the commonest solid tumours of female genital tract. 
      In this study myomectomy was the commonest used modality of 
treatment. 
      The majority of women were between 30 to 45 years old and the 
majority of them were nulliparous. 
Fertile women were noticed to be more in the whole population than infertile 
one .    
      Nearly half of the women were asymptomatic, while menstrual disorders 
occurred in approximately a quarter of the study population. 
      Women with fibroids of more than 16 weeks size were treated with 
abdominal hysterectomy more than with myomectomy. 
      Most of the women had more than one fibroid.     
      The recurrence rate of fibroids was close to that in the literature. 
      Abdominal hysterectomy was associated with more intraoperative blood 
loss and more blood transfusion than myomectomy. 
      Women with myomectomy had more postoperative complications    than 
those with abdominal hysterectomy.    
Recommendations 
 
- Myomectomy should be the treatment of choice for women with 
symptomatic uterine fibroids who desire future fertility but it carries the 
risk of recurrence.   
- Hysterectomy eliminates both current symptoms and the chance of 
recurrence. It should be used for women who completed their families. 
- Women should be counseled that hysterectomy is associated with less 
postoperative complication rate compared to myomectomy.  
 - Adequate amount of blood should be prepared for both hysterectomy 
and myomectomy. 
- Duration of hospital stay should be shortened in our hospitals taking in 
consideration more objective reasons for determination of postoperative 
hospital stay. Transverse pfannenstiel incision with subcutaneous closure 
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Myomectomy versus abdominal hysterectomy in 
management of uterine fibroid 
(Questionnaire) 
 
Serial No: ………… . 
.Age :  1 
   1. <30                2.  30 – 45          3.  >45  years 
.Marital status:2 
    1. single            2. Married          3. Widow / divorce     
3.Parity: 
    1.Nulliparous        2. 1- 4                 3. >4 
4.Infertility:     
    1. yes                 2. no 
  If yes duration of infertility: 
  1. <2 years          2. 2-5 years       3. >5 years                                                                            
5.C/0 : 
1. a symptomatic 
2. Menstrual disorders  
3. Pressure symptoms  
6.Post history: 
                1. No previous gynecological surgery .   
                2. previous Myomectomy 
        3.  Previous  c/s 
 O/E : 
7. Size of the fibroid . 
1. <12 weeks         2. 12-16 weeks      3.  >16 weeks   
8. Number of the fibroid . 
1. single               2. 2-5                 3. > 5  
9. Site of the fibroid . 
1. subserous           2. Intramural      3. Submucous  
10. Type of  anesthesia  
1. General             2.  Spinal                                      
11. Hb % preoperative. 
12. Hb % postoperative. 
13.Need for blood transfusion : 
  1. No                   2. 1-2 pints.          3. > 2pints.              
14.Hospital stay :  
         1. 4 -7days           2. >7days 
15.Postoperative complications :  
1. No              2. Fever        3. Abdominal pain        4. Bleeding .   
16.Type of operation   
  1. myomectomy      2. Abdominal hysterectomy .                                           
                                                                      
 
